Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from DocMorris ( (CH:DOCM) ) is now available.
DocMorris AG announced the final details of its planned capital increase, amounting to approximately CHF 200 million, during its General Meeting. The capital is intended to finance growth in prescription drugs and potentially repay a convertible bond. The company reported a 13.4% increase in external sales in the first quarter of 2025, despite a negative EBITDA, and continues to see growth in its Rx business and telemedicine services. The capital increase is expected to strengthen DocMorris’s market position and support its medium-term financial goals.
More about DocMorris
DocMorris AG is a leading company in online pharmacy, marketplace, and professional healthcare, with strong brands in Germany and other European countries. The company operates a highly automated logistics center in Heerlen, Netherlands, and leads marketplaces for health and care products in Southern Europe. DocMorris aims to create a digital health ecosystem, providing a wide range of products and services to manage health digitally.
Average Trading Volume: 138,134
Current Market Cap: CHF315.6M
For a thorough assessment of DOCM stock, go to TipRanks’ Stock Analysis page.